对照组以及组织型纤溶酶原激活物（t-PA）或纤溶酶原激活物抑制剂-1（PAI-1）水平升高的患者血浆中，t-PA与PAI-1抗原、活性以及t-PA/PAI-1复合物之间的相关性。 - Suppr | 超能文献

Correlations between t-PA and PAI-1 antigen and activity and t-PA/PAI-1 complexes in plasma of control subjects and of patients with increased t-PA or PAI-1 levels.

作者信息

Alessi M C, Juhan-Vague I, Declerck P J, Anfosso F, Gueunoun E, Collen D

机构信息

Laboratory of Hematology, CHU Timone, Marseille, France.

出版信息

Thromb Res. 1990 Dec 15;60(6):509-16. doi: 10.1016/0049-3848(90)90235-5.

DOI:10.1016/0049-3848(90)90235-5

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Correlations between t-PA and PAI-1 antigen and activity and t-PA/PAI-1 complexes in plasma of control subjects and of patients with increased t-PA or PAI-1 levels.对照组以及组织型纤溶酶原激活物（t-PA）或纤溶酶原激活物抑制剂-1（PAI-1）水平升高的患者血浆中，t-PA与PAI-1抗原、活性以及t-PA/PAI-1复合物之间的相关性。

Thromb Res. 1990 Dec 15;60(6):509-16. doi: 10.1016/0049-3848(90)90235-5.

2

Plasminogen activators and inhibitors in normal late pregnancy, postpartum and in the postnatal period.

Int J Gynaecol Obstet. 1992 May;38(1):9-18. doi: 10.1016/0020-7292(92)90723-v.

3

Fluctuations of euglobulin lysis time, tissue plasminogen activator, and free and total plasminogen activator inhibitor levels in plasma in daytime.白天血浆中优球蛋白溶解时间、组织型纤溶酶原激活物以及游离和总纤溶酶原激活物抑制剂水平的波动情况。

Thromb Res. 1990 Jan 1;57(1):13-20. doi: 10.1016/0049-3848(90)90191-e.

4

Effect of PAI-1 levels on the molar concentrations of active tissue plasminogen activator (t-PA) and t-PA/PAI-1 complex in plasma.

Blood. 1990 Sep 1;76(5):930-7.

5

[Tissue-type plasminogen activator and its inhibitor (PAI-1) in plasma in cases of non-insulin-dependent diabetes mellitus (NIDDM)].非胰岛素依赖型糖尿病（NIDDM）患者血浆中的组织型纤溶酶原激活物及其抑制剂（PAI-1）

Nihon Ronen Igakkai Zasshi. 1990 Nov;27(6):699-705. doi: 10.3143/geriatrics.27.699.

6

Tissue plasminogen activator, plasminogen activator inhibitors, and activator-inhibitor complex in liver disease.肝脏疾病中的组织型纤溶酶原激活剂、纤溶酶原激活剂抑制剂及激活剂-抑制剂复合物

J Clin Pathol. 1994 Mar;47(3):214-7. doi: 10.1136/jcp.47.3.214.

7

Changes in plasminogen activator inhibitor 1 and tissue-type plasminogen activator during exercise in patients with coronary artery disease.冠状动脉疾病患者运动期间纤溶酶原激活物抑制剂1和组织型纤溶酶原激活物的变化。

Haemostasis. 1990;20(5):305-12. doi: 10.1159/000216142.

8

Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.青少年血液纤溶成分的年龄依赖性以及低剂量口服避孕药对青少年凝血和纤溶的影响。

Thromb Haemost. 1988 Dec 22;60(3):361-4.

9

Plasminogen activators t-PA, u-PA and its inhibitor (PAI) in normal males and females.正常男性和女性体内的纤溶酶原激活剂组织型纤溶酶原激活剂（t-PA）、尿激酶型纤溶酶原激活剂（u-PA）及其抑制剂（PAI）。

Thromb Haemost. 1991 Nov 1;66(5):581-5.

10

[Tissue plasminogen activator (T-PA) and tissue plasminogen activator inhibitor (PAI-1) in patients after head injury].[颅脑损伤患者的组织型纤溶酶原激活剂（T-PA）和组织型纤溶酶原激活剂抑制剂（PAI-1）]

Neurol Neurochir Pol. 1996 May-Jun;30(3):427-34.

引用本文的文献

1

High Plasma tPAPAI-1C Levels May Be Related to a Poor Prognosis in Patients with Severe or Critical COVID-19: A Single-Center Retrospective Study.高血浆组织纤溶酶原激活物抑制因子-1抗原水平可能与重型或危重型新型冠状病毒肺炎患者的不良预后相关：一项单中心回顾性研究

J Clin Med. 2023 Mar 3;12(5):2019. doi: 10.3390/jcm12052019.